Hepatitis C

The 10-year cumulative incidences for HCC and mortality were significantly higher in the HBV cohort with heavy alcoholism than it was for either HBV alone or alcoholism alone.

Investigators articulated the development and validation of an enzyme-linked immunoassay against hepatitis C virus (HCV). They suggest the implementation of this low cost assay among at-risk populations.

The increase does not appear to have a negative impact on post transplant survival, investigators say.

There are several early phase trials underway for new hepatitis B virus treatments.

The goal for many is to eradicate HCV by the year 2030.

Dr. Sanyal talks about the importance in having ongoing real-world data for NAFLD and NASH.

ALT fluctuations remained stable for patients with NAFLD throughout disease progression.

The overall prevalence of NAFLD was 40.6%, with every NAFLD patient having a BMI of at least 25.

The results are consistent with the original analysis from 2019, where the treatment resulted in a statistically significant effect on fibrosis improvement.

Washington DC, Hawaii, Oklahoma, California, Tennessee, West Virginia, Mississippi, Oregon, Washington, Louisiana, Kentucky, and New York all had HBV-related mortality rates higher than the national average.

Tenofovir was linked to a decreased incidence rate of HCC compared to entecavir. However, this difference was not considered statistically significant.

Between 2015-2019 the number of HBV-related deaths increased by 2.9%.

Acute hepatitis of unknown etiology is not reportable in the US, making it difficult to understand whether recent levels are now reaching historic levels.

Patients with anti-HBs also had higher APRI scores, FIB-4 scores, and liver stiffness values.

For pediatric patients, the anti-HBs (+) rates were relatively stable at approximately 60%, but the anti-HBc (+) rates increased significantly with age.

Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.

At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

Patients with IBD are often at an increased risk of developing NAFLD.

Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.